Financial Data and Key Metrics - The company ended Q3 2024 with approximately $131 million in cash, cash equivalents, and marketable securities, compared to $132 million as of December 31, 2023 [19] - Net proceeds from the issuance of common shares under the at-the-market offering program were approximately $44 million in the first half of 2024, offset by $54.5 million of cash used in operations [19] - The company expects its 2024 cash burn to range between $63 million and $67 million, with sufficient cash runway to fund operations into Q4 2026 [20] Business Line Data and Key Metrics - The IM-PROVE I clinical trial showed that 33% of patients in Cohort A1 achieved sustained surface antigen loss at 24 weeks post-treatment, with 67% of patients with baseline surface antigen <1,000 IU/mL maintaining surface antigen loss [9][10] - In the IM-PROVE II trial, 95% of patients achieved surface antigen levels <100 IU/mL prior to dosing with VTP-300 or placebo, with more patients maintaining thresholds <100 or <10 IU/mL versus placebo [12] - AB-101, the oral small molecule PD-L1 checkpoint inhibitor, demonstrated dose-dependent receptor occupancy in Phase Ia/Ib trials, with 7 out of 8 subjects in the 25-milligram cohort showing >70% receptor occupancy [16] Market Data and Key Metrics - Chronic HBV affects over 250 million people globally, with current treatments offering a functional cure rate of less than 10% [6][25] - The company is focused on developing a functional cure for HBV, aiming for a 20% functional cure rate, which would significantly reduce the risk of liver cirrhosis and hepatocellular carcinoma [7][25] Company Strategy and Industry Competition - The company is advancing imdusiran into a Phase IIb clinical trial as a cornerstone in a potential HBV functional cure treatment regimen, combining it with immune modulators like interferon and VTP-300 [13] - AB-101 is being developed to enhance HBV-specific immune responses in combination with imdusiran, with preliminary data from HBV patients expected in the first half of 2025 [14][17] - The company is involved in litigation with Moderna and Pfizer/BioNTech regarding LNP intellectual property, with trial dates set for September 2025 and December 2024, respectively [18] Management Commentary on Operating Environment and Future Outlook - The company remains committed to transforming the HBV treatment landscape and providing hope to millions of patients worldwide [49] - Management is optimistic about the upcoming data presentations at AASLD, including updates from the IM-PROVE I trial and preliminary data from the nivolumab arm of the IM-PROVE II trial [21] Other Important Information - The company has achieved all of its second-half milestones, including reporting multiple ascending dose data from healthy subjects in the AB-101-001 trial [21] Q&A Session Summary Question: Functional Cure Data Expectations - The company has not presented functional cure data for imdusiran yet but aims for a 20% functional cure rate as a meaningful benchmark [24][25] - All subjects in the IM-PROVE I study received at least 4 doses of imdusiran, with Cohort A1 continuing imdusiran during interferon treatment, while Cohort A2 received only interferon after the initial 4 doses [26] Question: Denominator for Functional Cure Calculation - The denominator for functional cure in Cohort A1 is 12 patients, with 33% achieving surface antigen loss [29] - Patients with baseline surface antigen <1,000 IU/mL showed a 67% surface antigen loss rate, aligning with industry trends [30] Question: AB-101 Data and Study Design - Preliminary data from AB-101 in HBV patients is expected in the first half of 2025, with biomarker collection ongoing to assess receptor occupancy and immune response [39][40] - The company plans to combine AB-101 with imdusiran as quickly as possible, following monotherapy evaluation [42] Question: IM-PROVE II Data at AASLD - The AASLD presentation will focus on Group C of the IM-PROVE II study, which includes low-dose nivolumab [43] Question: Litigation Update - The claim construction hearing for the Pfizer/BioNTech lawsuit is scheduled for December 18, 2024, with a trial date for the Moderna case set for September 24, 2025 [18][45] Question: Cash Runway and ATM Program - The company's cash runway into Q4 2026 does not include any expected proceeds from the ATM program [48]

分组1 - Arbutus Biopharma reported a quarterly loss of $0.10 per share, which is in line with the Zacks Consensus Estimate, and an improvement from a loss of $0.12 per share a year ago [1] - The company posted revenues of $1.34 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 22.82%, and a significant decline from year-ago revenues of $4.66 million [2] - Over the last four quarters, Arbutus has not surpassed consensus EPS estimates and has topped consensus revenue estimates only once [2][1] 分组2 - Arbutus shares have increased approximately 58.4% since the beginning of the year, outperforming the S&P 500's gain of 21.2% [3] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for future stock performance [4] - The current consensus EPS estimate for the coming quarter is -$0.09 on revenues of $1.76 million, and for the current fiscal year, it is -$0.38 on revenues of $7.35 million [7] 分组3 - The Medical - Biomedical and Genetics industry, to which Arbutus belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Arbutus's stock performance [5] - The current estimate revisions trend for Arbutus is mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6]

EXHIBIT 99.1 Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update Imdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD - The Liver Meeting 2024 Multiple-ascending doses of AB-101 in healthy subjects in the Phase 1a/1b clinical trial were generally safe and well-tolerated with evidence of receptor occupancy Now dosing cHBV patients with AB-101 in Part 3 of the Phase 1a/1b clinical trial Cash runway into the fourth quarter of 2 ...

WARMINSTER, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its third quarter 2024 financial results and corporate update for Wednesday, November 6, 2024. The schedule for the press release and conference call/webcast are as follows ...

Group 1 - Arbutus Biopharma (ABUS) has gained approximately 60.8% year-to-date, outperforming the Medical sector average gain of 9.7% [2][3] - The Zacks Consensus Estimate for ABUS' full-year earnings has increased by 2.6% in the past quarter, indicating stronger analyst sentiment and an improving earnings outlook [2] - Arbutus Biopharma is ranked 6 in the Zacks Sector Rank and has a Zacks Rank of 2 (Buy), suggesting a favorable investment outlook [1][2] Group 2 - Arbutus Biopharma is part of the Medical - Biomedical and Genetics industry, which has seen an average loss of 0.3% year-to-date, highlighting ABUS's relative strength in this sector [3] - Astrazeneca (AZN), another outperforming stock in the Medical sector, has gained 14.1% year-to-date and has a Zacks Rank of 2 (Buy) [2][3] - The Large Cap Pharmaceuticals industry, to which Astrazeneca belongs, has performed well with a year-to-date increase of 22.7% [3]

Group 1 - Arbutus Biopharma (ABUS) has shown a year-to-date return of approximately 54.8%, significantly outperforming the Medical sector average return of 11.2% [2][3] - The Zacks Consensus Estimate for ABUS's full-year earnings has increased by 2.6% over the past quarter, indicating improved analyst sentiment [2] - Arbutus Biopharma is ranked 5 in the Zacks Sector Rank, which includes 1018 companies in the Medical group [1] Group 2 - Arbutus Biopharma belongs to the Medical - Biomedical and Genetics industry, which has an average year-to-date return of 3.3% [3] - Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) has a year-to-date return of 24.8% and is also ranked 2 (Buy) by Zacks [2][3] - The Medical - Drugs industry, to which Chugai belongs, has experienced a decline of -0.3% this year [3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to | --- | --- | --- | --- | |------------------------------------------------------------------------------|------------------------------------------------------------- ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Arbutus Biopharma (ABUS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Arbutus Biopharma is one of 1021 individual stocks in the Medical sector ...

Biotechnology firm Arbutus (NASDAQ:ABUS) — which specializes in virology — announced a major overhaul of its business. It will dramatically cut headcount in an effort to streamline operations and focus on its most promising therapeutic candidates. The Arbutus layoffs will result in a 40% reduction in the company’s workforce. Though steep, ABUS stock gained about 1% in the early afternoon session.According to a MarketWatch report, the notable aspect of the shakeup is that Arbutus “plans to cease all Hepatiti ...

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q2 2024 Earnings Conference Call August 1, 2024 8:45 AM ET Company Participants Lisa Caperelli - VP, Investor Relations Michael McElhaugh - Interim President, CEO & Director Karen Sims - Chief Medical Officer David Hastings - CFO Conference Call Participants Dennis Ding - Jefferies Roy Buchanan - JMP Securities Keay Nakae - Chardan Capital Markets Operator Good day, and thank you for standing by. Welcome to the Arbutus Biopharma 2024 Second Quarter Financial Resul ...